Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Studies for Recurrent Lung Cancer

 

PF-00299804 vs. Erlotinib for Advanced Non-Small Cell Lung Cancer (UW1108)
A Randomized, Double-Blind Phase 3 Study Of PF-00299804, A Pan-Her Inhibitor, Vs. Erlotinib For The Treatment Of Advanced Non-Small Cell Lung Cancer Following Progression After, Or Intolerance To, At Least One Prior Chemotherapy

Investigator: Renato G. Martins, MD, MPH;   Conditions: Non-Small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT01360554

Radiation Therapy + Cisplatin & Etoposide for Inoperable NSCLC (7506)
A Phase I dose-intensification study using radiation therapy and concurrent cisplatin and etoposide for patients with inoperable non-small cell lung cancer

Investigator: Shilpen Patel, MD;   Conditions: Lung Cancer; Solid Tumors;    Status: Recruiting;   Study ID: NCT01411098

Lucanix Vaccine Therapy for NSCLC (UW08006)
Phase III Lucanix™ Vaccine Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Following Front-Line Chemotherapy (STOP)

Investigator: Keith Eaton, MD, PhD;   Conditions: Lung Neoplasm, Carcinoma, Non-Small-Cell Lung: Stage IIIA (T3,N2 Only), Carcinoma, Non-Small-Cell Lung: Stage IIIB, Carcinoma, Non-Small-Cell Lung: Stage IV;    Status: Recruiting;   Study ID: NCT00676507

Erlotinib + OSI-906 for NSCLC (UW10054)
A Randomized, Double-Blind, Phase 2 Study of Erlotinib (Tarceva®) in Combination With OSI-906 or Placebo in Chemonaive Patients With Advanced NSCLC With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

Investigator: Keith Eaton, MD;   Conditions: NSCLC;    Status: Recruiting;   Study ID: NCT01221077

Erlotinib w/wo Carboplatin and Paclitaxel for Stage IIIB or Stage IV NSCLC (SWOG 0709)
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel (Taxol)/OSI- 774(Erlotinib (Tarceva); NSC-718781) or OSI-774 Alone in Advanced Non-Small Lung Cancer (NSCLC) Patients with Performance Status 2 (PS-2) Selected By Serum Proteomics

Investigator: Fred Appelbaum, MD;   Conditions: Lung Cancer;    Status: Recruiting;   Study ID: NCT00661193

MDX-1105 for Advanced or Recurrent Cancer (UW08038)
A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors

Investigator: Scott S. Tykodi, MD, PhD;   Conditions: Renal Cell Carcinoma, Non-small Cell Lung Cancer, Malignant Melanoma, Epithelial Ovarian Cancer, Colorectal Adenocarcinoma;    Status: Recruiting;   Study ID: NCT00729664

Topotecan With or Without Aflibercept for Extensive-Stage Small Cell Lung Cancer (SWOG 0802)
A Randomized Phase II Trial of Weekly Topotecan with and without AVE0005 (Aflibercept; NSC-724770) in Patients with Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC)

Investigator: Fred Appelbaum, MD;   Conditions: Lung Cancer;    Status: Recruiting;   Study ID: NCT00828139

LDK378 for Tumors with ALK Mutation (UW10038)
A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)

Investigator: Laura Chow, MD;   Conditions: Tumors Characterized by Genetic Abnormalities of ALK;    Status: Recruiting;   Study ID: NCT01283516

Onartuzumab (MetMAb) for Squamous Non-Small Cell Lung Cancer (UW11048)
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Gemcitabine + Cisplatin or Carboplatin as First-line Treatment for Patients With Stage IIIb or IV Squamous Non-small Cell Lung Cancer (NSCLC)

Investigator: Keith D. Eaton, MD;   Conditions: Non-Small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT01519804